Kobe2602
CAS No. : 454453-49-7
| Size | Price | Stock |
|---|---|---|
| 5mg | $25 | In-stock |
| 10mg | $35 | In-stock |
| 25mg | $60 | In-stock |
| 50mg | $90 | In-stock |
| 100mg | $144 | In-stock |
| 250mg | $288 | In-stock |
| 500 mg | Get quote | |
| 1 g | Get quote | |
| We match the lowest price on market. | ||
We offer a substantial discount on larger orders, please inquire via [email protected]
or Fax: (86)21-58955996
Inquiry for price and availability only. Please place your order via our email or fax.
| Cat. No. : | HY-15717 |
| M.Wt: | 419.31 |
| Formula: | C14H9F4N5O4S |
| Purity: | >98 % |
| Solubility: | H2O : ≥ mg/mL;DMSO : 200 mg/mL (ultrasonic) |
Kobe2602 is a Ras-Raf interaction inhibitor. Kobe2602 inhibits the binding of H-Ras·GTP to c-Raf-1 RBD with a Ki of 149 μM. Kobe2602 has antitumor activity[1].
IC50 & Target: Ki: 149 μM (Ras-Raf interaction)[1]
In Vitro: Kobe2602 (2-20 μM; 1 hour) exhibits Ras-Raf-binding inhibition in NIH 3T3 cells[1].
Kobe2602 has IC50 value of approximately 10 μM for the cellular Ras-Raf-binding inhibition[1].
Kobe2602 (20 μM) efficiently inhibits the phosphorylation of MEK and ERK, downstream kinases of Raf in NIH 3T3 cells transiently expressing H-RasG12V[1].
Kobe2602 inhibits Ras?GTP but not Ras?GDP[1].
Kobe2602 (20 μM) inhibits the anchorage-dependent proliferation of H-RasG12V-transformed cells[1].
In Vivo: Kobe2602 (80 mg/kg; p.o.; five consecutive days per week; for 17 days) exhibits antitumor activity on a xenograft of human colon carcinoma SW480 cells carrying the K-RasG12V gene[1].
Lorem ipsum dolor sit amet, consectetur adipisicing elit. Autem earum hic iste maiores, nam neque rem suscipit. Adipisci consequatur error exercitationem fugit ipsam optio qui, quibusdam repellendus sed vero! Debitis.
Inquiry Information- Product Name:
- Kobe2602
- Cat. No.:
- HY-15717
- Quantity:
Your information is safe with us.